ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
2023年6月14日 - 9:31PM
ReShape Lifesciences Inc. (Nasdaq: RSLS), the
premier physician-led weight loss and metabolic health solutions
company, today announced participation in the following investor
and industry conferences in June:
- June 20-21: Maxim Virtual
Healthcare Conference. Paul F. Hickey, President and Chief
Executive Officer, and Tom Stankovich, Chief Financial Officer,
will present a company overview at this virtual conference on
Tuesday, June 20, 2023, at 2:00 pm ET. A live webcast of the
presentation will be available on the “Events and Presentations”
section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations. An
archived replay will be available on the company’s website for a
period of 90 days after the conference.
- June 22: Life Sciences
Investor Forum. Messrs. Hickey and Stankovich will present
a company overview at this virtual conference on Thursday, June 22,
2023, at 11:00 am ET. Interested parties can register to view the
live presentation at www.virtualinvestorconferences.com.
- June 25-27: American
Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual
Meeting. Jonathan J. Waataja, Ph.D., Director of Research
at ReShape Lifesciences, will present data on the company’s
Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system in a virtual
e-poster at this meeting being held in Las Vegas, NV, June 25 - 29,
2023.
- Poster Title: The
Insulin Response to Oral Glucose Tolerance Tests did not Diminish
Following Prolonged Stimulation of the Vagus Nerve Celiac Branch in
the Study of a Novel Bioelectronic Treatment for Type 2 Diabetes
Mellitus
- Author: Jonathan
J. Waataja, Ph.D.
- Session:
E-Posters
- Date: June 27,
2023
- Time: 9:00 am -
12:30 pm PT
About ReShape
Lifesciences®ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. ReShape Marketplace™ is
an online collection of quality wellness products curated for all
consumers to help them achieve their health goals. The
investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system
utilizes a proprietary vagus nerve block and stimulation technology
platform for the treatment of Type 2 diabetes and metabolic
disorders. The Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor
Statement This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as "expect," "plan,"
"anticipate," "could," "may," "intend," "will," "continue,"
"future," other words of similar meaning and the use of future
dates. Forward-looking statements in this press release include the
statements that we expect feedback on the PMA submission from the
FDA by year end, and, if approved, that we believe based on
physician feedback that there will be broad adoption of the
Lap-Band® 2.0 by existing Lap-Band® surgeons and surgeons that
newly adopt the Lap-Band® 2.0. These and additional risks and
uncertainties are described more fully in the company's filings
with the Securities and Exchange Commission, including those
factors identified as "risk factors" in our most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
We are providing this information as of the date of this press
release and do not undertake any obligation to update any
forward-looking statements contained in this document as a result
of new information, future events or otherwise, except as required
by law.
CONTACTSReShape
Lifesciences Investor Contact:Thomas StankovichChief
Financial Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
過去 株価チャート
から 4 2024 まで 5 2024
ReShape Lifesciences (NASDAQ:RSLS)
過去 株価チャート
から 5 2023 まで 5 2024